Cereno Scientific to present CS585’s preclinical data at scientific congress ACC.23/WC
Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS585 has been accepted as a moderated poster presentation at the ACC.23/WCC hosted by the American College of Cardiology Together With WCC (World Congress of Cardiology), in New Orleans, US, on March 4-6, 2023. The abstract titled “CS585 is a novel orally available prostacyclin receptor agonist with long-term in vivo inhibition of platelets and thrombosis formation in mouse without increased risk of bleeding” will be presented by Dr. Michael Holinstat, lead of Cereno’s development programs at